Cutaneous Squamous Cell Carcinoma (cSCC) | Norton Healthcare

Indication: Cutaneous Squamous Cell Carcinoma (cSCC)

A Randomized, Placebo-Controlled, Double-Blind Study Of Adjuvant Cemiplimab Versus Placebo After Surgery And Radiation Therapy In Patients With High Risk Cutaneous Squamous Cell Carcinoma

High Risk Patients

Sub-indication: High risk CSCC (after surgery and RT)

Line of Therapy: Adjuvant

Drug Study

Principal Investigator: Jae Jung, M.D.
Norton Cancer Institute

Sponsor: Regeneron Pharmaceuticals, Inc.

Learn more at ClinicalTrials.gov

Email for more information: Derm-NCIResearch@nortonhealthcare.org

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.